Haemonetics
About: Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
Employees: 3,023
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
29% more call options, than puts
Call options by funds: $26M | Put options by funds: $20.1M
22% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 45
22% more repeat investments, than reductions
Existing positions increased: 124 | Existing positions reduced: 102
2% more funds holding
Funds holding: 306 [Q4 2024] → 312 (+6) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 4 [Q4 2024] → 4 (+0) [Q1 2025]
4.67% less ownership
Funds ownership: 112.62% [Q4 2024] → 107.95% (-4.67%) [Q1 2025]
23% less capital invested
Capital invested by funds: $4.42B [Q4 2024] → $3.41B (-$1B) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$84
20%
upside
Avg. target
$96
37%
upside
High target
$105
50%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
JMP Securities David Turkaly | 43%upside $100 | Market Outperform Reiterated | 20 May 2025 |
Raymond James Andrew Cooper | 50%upside $105 | Strong Buy Reiterated | 9 May 2025 |
Needham Mike Matson | 20%upside $84 | Buy Maintained | 8 May 2025 |
Financial journalist opinion
Neutral
PRNewsWire
2 weeks ago
Haemonetics to Present at Goldman Sachs 46th Annual Global Healthcare Conference
BOSTON , May 30, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that Chris Simon, President and CEO, will participate in a fireside chat with investors at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 8:40 a.m. ET. The public may access a live webcast of the fireside chat at Haemonetics' Investor Relations website or at the following link: https://event.webcasts.com/starthere.jsp?ei=1721260&tp_key=3096fdc651&tp_special=8 A replay of the recorded webcast will become accessible 12 hours after the event and will be available for 90 days on Haemonetics' Investor Relations website.
Positive
Zacks Investment Research
1 month ago
HAE Stock Gains on Q4 Earnings and Revenue Beat, Margins Up
Haemonetics' fourth-quarter fiscal 2025 results reflect the positive impact of its long-term plan, with meaningful earnings growth and margin expansion.
Neutral
Seeking Alpha
1 month ago
Haemonetics Corporation (HAE) Q4 2025 Earnings Call Transcript
Haemonetics Corporation (NYSE:HAE ) Q4 2025 Earnings Conference Call May 8, 2025 8:00 AM ET Company Participants Olga Guyette – Vice President-Investor Relations & Treasury Chris Simon – Chief Executive Officer James D'Arecca – Chief Financial Officer Conference Call Participants Rohin Patel – JPMorgan Marie Thibault – BTIG Mike Matson – Needham & Company Andrew Cooper – Raymond James Joanne Wuensch – Citi Anthony Petrone – Mizuho Financial Group Michael Petusky – Barrington Research Craig Bijou – Bank of America Securities Operator Good day, and thank you for standing by. Welcome to the Q4 2025 Haemonetics Corporation Earnings Conference Call.
Positive
Zacks Investment Research
1 month ago
Here's What Key Metrics Tell Us About Haemonetics (HAE) Q4 Earnings
The headline numbers for Haemonetics (HAE) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Positive
Zacks Investment Research
1 month ago
Haemonetics (HAE) Q4 Earnings and Revenues Surpass Estimates
Haemonetics (HAE) came out with quarterly earnings of $1.24 per share, beating the Zacks Consensus Estimate of $1.22 per share. This compares to earnings of $0.90 per share a year ago.
Neutral
PRNewsWire
1 month ago
Haemonetics 4th Quarter and Fiscal Year 2025 Earnings Release Available on Investor Relations Website
Financial release accessible online BOSTON , May 8, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its fourth quarter and fiscal year 2025, which ended March 29, 2025, are available on its Investor Relations website. The Company will host a conference call and webcast with investors and analysts to discuss and answer questions about the results at 8:00 a.m.
Positive
Zacks Investment Research
1 month ago
Gear Up for Haemonetics (HAE) Q4 Earnings: Wall Street Estimates for Key Metrics
Besides Wall Street's top -and-bottom-line estimates for Haemonetics (HAE), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2025.
Positive
Zacks Investment Research
1 month ago
Haemonetics (HAE) Earnings Expected to Grow: Should You Buy?
Haemonetics (HAE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Positive
Zacks Investment Research
1 month ago
4 MedTech Stocks Poised to Outshine Q1 Earnings Estimates
MedTech companies' quarterly results are likely to reflect base business recovery on a year-over-year basis. Let's see how HIMS, GMED, QDRL and HAE are poised ahead of their earnings release.
Neutral
PRNewsWire
2 months ago
Haemonetics Sets Date for Publishing Fourth Quarter and Fiscal Year 2025 Results: May 8, 2025
BOSTON , March 31, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish fourth quarter and fiscal year 2025 financial results at 6:00 am ET on Thursday, May 8, 2025. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am ET on May 8, 2025.
Charts implemented using Lightweight Charts™